Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis

Abstract

Introduction

Offering iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for recurrence of peritoneal carcinomatosis (PC) poses a surgical dilemma. Safety of this repeated operation in the short and long term has not been largely investigated.

Methods

Patients with PC who underwent 377 CRS/HIPEC procedures between 2007 and 2018 at our institution were included from a prospectively maintained database. Outcomes for patients who had singular CRS/HIPEC were compared with those for patients who had repeated CRS/HIPEC.

Results

Overall, there were 325 singular and 52 iterative CRS/HIPEC procedures performed during this time period. Age, sex, and ASA class were comparable between cohorts (p = NS). Optimal cytoreduction, mean operative time, mean length of hospital stay, 90-day major morbidity, and 90-day mortality were also similar. At a median follow-up of 24 months, there was no significant difference in recurrence rate (%, 60 vs 63, p = 0.76), disease-free survival (mean months, 19 vs 15, p = 0.30), and overall survival (mean months, 32 vs 27, p = 0.69). The iterative CRS/HIPEC group had significantly higher rates of major late complications than the singular CRS/HIPEC group (%, 18 vs 40, p < 0.01).

Conclusion

Repeated CRS/HIPEC for PC has similar perioperative morbidity and mortality, as well as long-term oncological benefits, when compared with singular CRS/HIPEC. However, more than twice as many patients undergoing iterative CRS/HIPEC suffered from major late complications.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Tabrizian P, Shrager B, Jibara G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014;18:1024. https://doi.org/10.1007/s11605-014-2477-5.

  2. 2.

    Spratt J, Adcock R, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–60.

  3. 3.

    Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000; 88:2512e9.

  4. 4.

    Verwaal VJ, Bruin S, Boot H, et al. 8 years follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426e32.

  5. 5.

    Esquivel J. Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan and Korea. Cancer J. 2009;15:249–54.

  6. 6.

    Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21:1501. https://doi.org/10.1245/s10434-013-3061-z.

  7. 7.

    Leapman MS, Jibara G, Tabrizian, P, et al. Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study. Ann Surg Oncol. 2014;21:1153. https://doi.org/10.1245/s10434-013-3393-8.

  8. 8.

    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.

  9. 9.

    Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.

  10. 10.

    Verwaal VJ. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J. 2009;15:212–5.

  11. 11.

    Golas N, Bakrin N, Passot G. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106:197–203.

  12. 12.

    Vassos N, Förtsch T, Aladashvili A. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. World J Surg Oncol. 2016;14:42. https://doi.org/10.1186/s12957-016-0804-x.

  13. 13.

    Wong J, Koch AL, Deneve JL. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014;21:1480–6. https://doi.org/10.1245/s10434-013-3341-7.

  14. 14.

    Sardi A, Jimenez WA, Nieroda C. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: Analysis of survival outcomes. EJSO. 2013;39:1207e1213.

  15. 15.

    Huang Y, Alzahrani NA, Liauw W. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. EJSO. 2015;41:1373e1378.

  16. 16.

    Konstantinidis LD, Levine EA, Chouliaras K. Interval between cytoreductions as a marker of tumor biology in selecting patients for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;116:741–5. https://doi.org/10.1002/jso.24703.

  17. 17.

    Vaira M, Robella M, Mellano A. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperth. 2014;30(8):565–9. https://doi.org/10.3109/02656736.2014.974693.

  18. 18.

    Kitai T, Yamanaka K. Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin. Int J Clin Oncol. 2018;23:298–304. https://doi.org/10.1007/s10147-017-1217-8.

  19. 19.

    Konstantinos IV, Chukwuemeka I, Perry S. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215:412–7.

  20. 20.

    Choudry HA, Bednar F, Shuai Y, et al. Repeat cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion is feasible and offers survival benefit in select patients with peritoneal metastases. Ann Surg Oncol. 2019;26:1445–53.

  21. 21.

    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359e74.

  22. 22.

    Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.

  23. 23.

    Suter M, Calmes JM, Paroz A, et al. A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. Obes Surg. 2006;16:829. https://doi.org/10.1381/096089206777822359.

  24. 24.

    Eifel PJ, Jhingran A, Bodurka DC, et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol. 2002;20(17):3651–7.

  25. 25.

    Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol. 2002;39(6):1061–5. https://doi.org/10.1016/s0735-1097(02)01711-4.

  26. 26.

    Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001;59(2):139–144. https://doi.org/10.1016/S0167-8140(00)00328-5.

  27. 27.

    Ilecchia G, Boru CE, Mouiel J, et al. The use of fibrin sealant to prevent major complications following laparoscopic gastric bypass: results of a multicenter, randomized trial. Surg Endosc. 2008;22:2492. https://doi.org/10.1007/s00464-008-9885-0.

  28. 28.

    Grosso G, Biondi A, Marventano S, et al. Major postoperative complications and survival for colon cancer elderly patients. BMC Surg. 2012;12(Suppl 1):S20. https://doi.org/10.1186/1471-2482-12-S1-S20.

  29. 29.

    Takeda A, Shigematsu N, Suzuki S, et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys. 1999;44(3):599–605. https://doi.org/10.1016/S0360-3016(99)00057-7.

  30. 30.

    Huisman MG, Audisio RA, Ugolini G, et al. Screening for predictors of adverse outcome in onco-geriatric surgical patients: a multicenter prospective cohort study. Eur J Surg Oncol. 2015;41(7):844–51. https://doi.org/10.1016/j.ejso.2015.02.018.

  31. 31.

    Hackett NJ, De Oliveira GS, Jain UK, et al. ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg. 2015;18:184–90. https://doi.org/10.1016/j.ijsu.2015.04.079.

  32. 32.

    Brooks-Brunn JA; Predictors of postoperative pulmonary complications following abdominal surgery. Chest. 1997;111(3):564–71. https://doi.org/10.1378/chest.111.3.564.

  33. 33.

    Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491. https://doi.org/10.1245/ASO.2006.05.013.

  34. 34.

    Fehniger J, Thomas S, Lengyel E, et al. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016;142(1):169–75. https://doi.org/10.1016/j.ygyno.2016.04.018.

  35. 35.

    Queiroz MA, Kubik-Huch RA, Hauser N, et al. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. Eur Radiol. 2015;25:2222. https://doi.org/10.1007/s00330-015-3657-8.

  36. 36.

    Xin J, Ma Q, Guo Q, et al. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer. Eur J Radiol. 2016;85(4):751–59. https://doi.org/10.1016/j.ejrad.2016.01.010.

  37. 37.

    Engbersen MP, Sant IV, Lok C, et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol. 2019;114:146–51. https://doi.org/10.1016/j.ejrad.2019.03.007.

  38. 38.

    Delhorme JB, Triki E, Romain B, et al. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis. J Visc Surg. 2015;152(3):149–54. https://doi.org/10.1016/j.jviscsurg.2015.01.002.

  39. 39.

    Baratti D, Kusamura S, Deraco M. Colorectal cancer peritoneal metastases: second-look laparotomy, prophylactic HIPEC, or both? Ann Surg. 2016;263(1):e5. https://doi.org/10.1097/sla.0000000000000773.

  40. 40.

    Elias D, Goere D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247(3):445–50. https://doi.org/10.1097/sla.0b013e31815f0113.

  41. 41.

    Bastiaenen VP, Klaver C, Kok N, et al. Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial. BMC Cancer. 2019;19:254. https://doi.org/10.1186/s12885-019-5408-8.

  42. 42.

    Smeenk R, Verwaal V, Zoetmulder F. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408–14.

  43. 43.

    Yan T, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. A journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14:2270–80.

  44. 44.

    Moran B. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health. 2006;28:375–8.

  45. 45.

    Cavaliere F, Valle M, De Rosa B, et al. Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve. Suppl Tumori. 2005;3:119–21.

Download references

Author information

Correspondence to Eliahu Bekhor MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bekhor, E., Carr, J., Hofstedt, M. et al. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis. Ann Surg Oncol (2019). https://doi.org/10.1245/s10434-019-08141-w

Download citation